Genetic markers inCYP2C19andCYP2B6for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus-Reference-Cited by-同舟云学术

Genetic markers inCYP2C19andCYP2B6for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus

Published:2015-12-25 Issue:2 Volume:81 Page:327-340
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Shu Wenying¹²,Guan Su³,Yang Xiuyan⁴,Liang Liuqin⁴,Li Jiali¹,Chen Zhuojia¹,Zhang Yu¹,Chen Lingyan¹,Wang Xueding¹,Huang Min¹

Affiliation:

1. Institute of Clinical Pharmacology, School of Pharmaceutical Sciences; Sun Yat-sen University; Guangzhou 510006

2. Department of Pharmacy; Cancer Center of Guangzhou Medical University; Guangzhou 510182

3. School of Bioscience and Biotechnology; South China University of Technology; Guangzhou 510006

4. Department of Rheumatology and Clinical Immunology; The First Affiliated Hospital of Sun Yat-sen University; Guangzhou 510080 China

Funder

National Natural Science Foundation of China

National Major Scientific and Technological Special Project

Fundamental Research Funds for the Central Universities

Guangzhou Medical University Scientific Research Program for Young Scientists

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12800/fullpdf

Reference47 articles.

1. Cyclophosphamide: new approaches for systemic lupus erythematosus;Petri;Lupus,2004

2. Strategies for preservation of ovarian and testicular function after immunosuppression;Pendse;Am J Kidney Dis,2004

3. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus;Zhong;Br J Clin Pharmacol,2006

4. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation;Xie;Pharmacogenomics J,2003

5. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles;Roy;Drug Metab Dispos,1999

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis;Pharmacogenetics and Genomics;2023-08-24

2. Cyclophosphamide induced intestinal injury is alleviated by blocking the TLR9/caspase3/GSDME mediated intestinal epithelium pyroptosis;International Immunopharmacology;2023-06

3. Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer;Supportive Care in Cancer;2022-05-24

4. White paper: Oncofertility in pediatric patients with Wilms tumor;International Journal of Cancer;2022-05-11

5. Research on DCE-MRI Images Based on Deep Transfer Learning in Breast Cancer Adjuvant Curative Effect Prediction;Journal of Healthcare Engineering;2022-02-23